Cargando…
Methylprednisolone Protects Cardiac Pumping Mechanics from Deteriorating in Lipopolysaccharide-Treated Rats
It has been shown that a prolonged low-dose corticosteroid treatment attenuates the severity of inflammation and the intensity and duration of organ system failure. In the present study, we determined whether low-dose methylprednisolone (a synthetic glucocorticoid) can protect male Wistar rats again...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659924/ https://www.ncbi.nlm.nih.gov/pubmed/26635633 http://dx.doi.org/10.3389/fphys.2015.00348 |
_version_ | 1782402698154344448 |
---|---|
author | Ko, Ya-Hui Tsai, Ming-Shian Chang, Ru-Wen Chang, Chun-Yi Wang, Chih-Hsien Wu, Ming-Shiou Liang, Jin-Tung Chang, Kuo-Chu |
author_facet | Ko, Ya-Hui Tsai, Ming-Shian Chang, Ru-Wen Chang, Chun-Yi Wang, Chih-Hsien Wu, Ming-Shiou Liang, Jin-Tung Chang, Kuo-Chu |
author_sort | Ko, Ya-Hui |
collection | PubMed |
description | It has been shown that a prolonged low-dose corticosteroid treatment attenuates the severity of inflammation and the intensity and duration of organ system failure. In the present study, we determined whether low-dose methylprednisolone (a synthetic glucocorticoid) can protect male Wistar rats against cardiac pumping defects caused by lipopolysaccharide-induced chronic inflammation. For the induction of chronic inflammation, a slow-release ALZET osmotic pump was subcutaneously implanted to infuse lipopolysaccharide (1 mg kg(−1) d(−1)) for 2 weeks. The lipopolysaccharide-challenged rats were treated on a daily basis with intraperitoneal injection of methylprednisolone (5 mg kg(−1) d(−1)) for 2 weeks. Under conditions of anesthesia and open chest, we recorded left ventricular (LV) pressure and ascending aortic flow signals to calculate the maximal systolic elastance (E(max)) and the theoretical maximum flow (Q(max)), using the elastance-resistance model. Physically, E(max) reflects the contractility of the myocardium as an intact heart, whereas Q(max) has an inverse relationship with the LV internal resistance. Compared with the sham rats, the cardiodynamic condition was characterized by a decline in E(max) associated with the increased Q(max) in the lipopolysaccharide-treated rats. Methylprednisolone therapy increased E(max), which suggests that the drug may have protected the contractile status from deteriorating in the inflamed heart. By contrast, methylprednisolone therapy considerably reduced Q(max), indicating that the drug may have normalized the LV internal resistance. In parallel, the benefits of methylprednisolone on the LV systolic pumping mechanics were associated with the reduced cardiac levels of negative inotropic molecules such as peroxynitrite, malondialdehyde, and high-mobility group box 1 protein. Based on these data, we suggested that low-dose methylprednisolone might prevent lipopolysaccharide-induced decline in cardiac intrinsic contractility and LV internal resistance, possibly through its ability to reduce the aforementioned myocardial depressant substances. However, since our results were obtained in anesthetized open-chest rats, extrapolation to what may occur in conscious intact animals should be done with caution. |
format | Online Article Text |
id | pubmed-4659924 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-46599242015-12-03 Methylprednisolone Protects Cardiac Pumping Mechanics from Deteriorating in Lipopolysaccharide-Treated Rats Ko, Ya-Hui Tsai, Ming-Shian Chang, Ru-Wen Chang, Chun-Yi Wang, Chih-Hsien Wu, Ming-Shiou Liang, Jin-Tung Chang, Kuo-Chu Front Physiol Physiology It has been shown that a prolonged low-dose corticosteroid treatment attenuates the severity of inflammation and the intensity and duration of organ system failure. In the present study, we determined whether low-dose methylprednisolone (a synthetic glucocorticoid) can protect male Wistar rats against cardiac pumping defects caused by lipopolysaccharide-induced chronic inflammation. For the induction of chronic inflammation, a slow-release ALZET osmotic pump was subcutaneously implanted to infuse lipopolysaccharide (1 mg kg(−1) d(−1)) for 2 weeks. The lipopolysaccharide-challenged rats were treated on a daily basis with intraperitoneal injection of methylprednisolone (5 mg kg(−1) d(−1)) for 2 weeks. Under conditions of anesthesia and open chest, we recorded left ventricular (LV) pressure and ascending aortic flow signals to calculate the maximal systolic elastance (E(max)) and the theoretical maximum flow (Q(max)), using the elastance-resistance model. Physically, E(max) reflects the contractility of the myocardium as an intact heart, whereas Q(max) has an inverse relationship with the LV internal resistance. Compared with the sham rats, the cardiodynamic condition was characterized by a decline in E(max) associated with the increased Q(max) in the lipopolysaccharide-treated rats. Methylprednisolone therapy increased E(max), which suggests that the drug may have protected the contractile status from deteriorating in the inflamed heart. By contrast, methylprednisolone therapy considerably reduced Q(max), indicating that the drug may have normalized the LV internal resistance. In parallel, the benefits of methylprednisolone on the LV systolic pumping mechanics were associated with the reduced cardiac levels of negative inotropic molecules such as peroxynitrite, malondialdehyde, and high-mobility group box 1 protein. Based on these data, we suggested that low-dose methylprednisolone might prevent lipopolysaccharide-induced decline in cardiac intrinsic contractility and LV internal resistance, possibly through its ability to reduce the aforementioned myocardial depressant substances. However, since our results were obtained in anesthetized open-chest rats, extrapolation to what may occur in conscious intact animals should be done with caution. Frontiers Media S.A. 2015-11-26 /pmc/articles/PMC4659924/ /pubmed/26635633 http://dx.doi.org/10.3389/fphys.2015.00348 Text en Copyright © 2015 Ko, Tsai, Chang, Chang, Wang, Wu, Liang and Chang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Physiology Ko, Ya-Hui Tsai, Ming-Shian Chang, Ru-Wen Chang, Chun-Yi Wang, Chih-Hsien Wu, Ming-Shiou Liang, Jin-Tung Chang, Kuo-Chu Methylprednisolone Protects Cardiac Pumping Mechanics from Deteriorating in Lipopolysaccharide-Treated Rats |
title | Methylprednisolone Protects Cardiac Pumping Mechanics from Deteriorating in Lipopolysaccharide-Treated Rats |
title_full | Methylprednisolone Protects Cardiac Pumping Mechanics from Deteriorating in Lipopolysaccharide-Treated Rats |
title_fullStr | Methylprednisolone Protects Cardiac Pumping Mechanics from Deteriorating in Lipopolysaccharide-Treated Rats |
title_full_unstemmed | Methylprednisolone Protects Cardiac Pumping Mechanics from Deteriorating in Lipopolysaccharide-Treated Rats |
title_short | Methylprednisolone Protects Cardiac Pumping Mechanics from Deteriorating in Lipopolysaccharide-Treated Rats |
title_sort | methylprednisolone protects cardiac pumping mechanics from deteriorating in lipopolysaccharide-treated rats |
topic | Physiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659924/ https://www.ncbi.nlm.nih.gov/pubmed/26635633 http://dx.doi.org/10.3389/fphys.2015.00348 |
work_keys_str_mv | AT koyahui methylprednisoloneprotectscardiacpumpingmechanicsfromdeterioratinginlipopolysaccharidetreatedrats AT tsaimingshian methylprednisoloneprotectscardiacpumpingmechanicsfromdeterioratinginlipopolysaccharidetreatedrats AT changruwen methylprednisoloneprotectscardiacpumpingmechanicsfromdeterioratinginlipopolysaccharidetreatedrats AT changchunyi methylprednisoloneprotectscardiacpumpingmechanicsfromdeterioratinginlipopolysaccharidetreatedrats AT wangchihhsien methylprednisoloneprotectscardiacpumpingmechanicsfromdeterioratinginlipopolysaccharidetreatedrats AT wumingshiou methylprednisoloneprotectscardiacpumpingmechanicsfromdeterioratinginlipopolysaccharidetreatedrats AT liangjintung methylprednisoloneprotectscardiacpumpingmechanicsfromdeterioratinginlipopolysaccharidetreatedrats AT changkuochu methylprednisoloneprotectscardiacpumpingmechanicsfromdeterioratinginlipopolysaccharidetreatedrats |